349 related articles for article (PubMed ID: 32113143)
61. Cytokine Release Syndrome in the Pediatric Population and Implications for Intensive Care Management.
Romano J; Wilsterman E; Toal M; Joyce C
Crit Care Clin; 2023 Apr; 39(2):277-285. PubMed ID: 36898773
[TBL] [Abstract][Full Text] [Related]
62. Targeting CDK7 suppresses super enhancer-linked inflammatory genes and alleviates CAR T cell-induced cytokine release syndrome.
Wei Y; Li C; Bian H; Qian W; Jin K; Xu T; Guo X; Lu X; Su F
Mol Cancer; 2021 Jan; 20(1):5. PubMed ID: 33397398
[TBL] [Abstract][Full Text] [Related]
63. Chimeric antigen receptor T-cell therapy: An emergency medicine focused review.
Long B; Yoo MJ; Brady WJ; Holian A; Sudhir A; Gottlieb M
Am J Emerg Med; 2021 Dec; 50():369-375. PubMed ID: 34461398
[TBL] [Abstract][Full Text] [Related]
64. Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products.
Hunter BD; Rogalski M; Jacobson CA
Expert Opin Biol Ther; 2019 Nov; 19(11):1157-1164. PubMed ID: 31342797
[No Abstract] [Full Text] [Related]
65. Chimeric Antigen Receptor T-Cell Therapy for Cancer and Heart: JACC Council Perspectives.
Ganatra S; Carver JR; Hayek SS; Ky B; Leja MJ; Lenihan DJ; Lenneman C; Mousavi N; Park JH; Perales MA; Ryan TD; Scherrer-Crosbie M; Steingart RM; Yang EH; Zaha V; Barac A; Liu JE
J Am Coll Cardiol; 2019 Dec; 74(25):3153-3163. PubMed ID: 31856973
[TBL] [Abstract][Full Text] [Related]
66. Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel.
Porter D; Frey N; Wood PA; Weng Y; Grupp SA
J Hematol Oncol; 2018 Mar; 11(1):35. PubMed ID: 29499750
[TBL] [Abstract][Full Text] [Related]
67. [Practical aspects of the application of CAR T cells and management of their toxicities].
Bücklein V; Blumenberg V; Subklewe M
Dtsch Med Wochenschr; 2021 Sep; 146(17):1129-1137. PubMed ID: 34448189
[TBL] [Abstract][Full Text] [Related]
68. Cytokine release syndrome. Reviewing a new entity in the intensive care unit.
García Roche A; Díaz Lagares C; Élez E; Ferrer Roca R
Med Intensiva (Engl Ed); 2019 Nov; 43(8):480-488. PubMed ID: 30922608
[TBL] [Abstract][Full Text] [Related]
69. Cytokine Release Syndrome With the Novel Treatments of Acute Lymphoblastic Leukemia: Pathophysiology, Prevention, and Treatment.
Aldoss I; Khaled SK; Budde E; Stein AS
Curr Oncol Rep; 2019 Jan; 21(1):4. PubMed ID: 30666425
[TBL] [Abstract][Full Text] [Related]
70. EASIX and Severe Endothelial Complications After CD19-Directed CAR-T Cell Therapy-A Cohort Study.
Korell F; Penack O; Mattie M; Schreck N; Benner A; Krzykalla J; Wang Z; Schmitt M; Bullinger L; Müller-Tidow C; Dreger P; Luft T
Front Immunol; 2022; 13():877477. PubMed ID: 35464403
[TBL] [Abstract][Full Text] [Related]
71. Adjuvant ruxolitinib therapy relieves steroid-refractory cytokine-release syndrome without impairing chimeric antigen receptor-modified T-cell function.
Wei S; Gu R; Xu Y; Liu X; Xing Y; Gong X; Zhou C; Liu B; Zhang G; Liu K; Wei H; Mi Y; Wang M; Wang Y; Wang J
Immunotherapy; 2020 Oct; 12(14):1047-1052. PubMed ID: 32777959
[No Abstract] [Full Text] [Related]
72. [Analysis of Related Early Warning Indexes of Cytokine Release Syndrome in Multiple Myeloma Patients after CAR-T Treatment].
Ye CY; Zhao LN; Wang SY; Cheng H; Chen W; Qi KM; Wu QY; Li ZY; Xu KL; Cao J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1203-1208. PubMed ID: 34362503
[TBL] [Abstract][Full Text] [Related]
73. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy.
Hay KA
Br J Haematol; 2018 Nov; 183(3):364-374. PubMed ID: 30407609
[TBL] [Abstract][Full Text] [Related]
74. Cardiovascular Toxicities with Chimeric Antigen Receptor T-cell Therapy.
Gill J
Curr Cardiol Rev; 2023; 19(1):e230622206353. PubMed ID: 35747980
[TBL] [Abstract][Full Text] [Related]
75. Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy.
Hu Y; Sun J; Wu Z; Yu J; Cui Q; Pu C; Liang B; Luo Y; Shi J; Jin A; Xiao L; Huang H
J Hematol Oncol; 2016 Aug; 9(1):70. PubMed ID: 27526682
[TBL] [Abstract][Full Text] [Related]
76. Chimeric antigen receptor T cell therapy and nephrotoxicity: From diagnosis to treatment strategies.
Zhou H; Yang M; Cui L; Jiang J
Int Immunopharmacol; 2020 Dec; 89(Pt B):107072. PubMed ID: 33059198
[TBL] [Abstract][Full Text] [Related]
77. Cytokine Release Syndrome Biology and Management.
Cobb DA; Lee DW
Cancer J; 2021 Mar-Apr 01; 27(2):119-125. PubMed ID: 33750071
[TBL] [Abstract][Full Text] [Related]
78. The differential effects of tumor burdens on predicting the net benefits of ssCART-19 cell treatment on r/r B-ALL patients.
Li M; Xue SL; Tang X; Xu J; Chen S; Han Y; Qiu H; Miao M; Xu N; Tan J; Kang L; Yu Z; Lou X; Xu Y; Chen J; Yan Z; Feng W; Wu D; Yu L
Sci Rep; 2022 Jan; 12(1):378. PubMed ID: 35013456
[TBL] [Abstract][Full Text] [Related]
79. Chimeric antigen receptor T-cells safety: A pharmacovigilance and meta-analysis study.
Dolladille C; Ederhy S; Ezine E; Choquet S; Nguyen LS; Alexandre J; Moslehi JJ; Dechartres A; Salem JE
Am J Hematol; 2021 Sep; 96(9):1101-1111. PubMed ID: 34057232
[TBL] [Abstract][Full Text] [Related]
80. IL-6: from arthritis to CAR-T-cell therapy and COVID-19.
Kishimoto T
Int Immunol; 2021 Sep; 33(10):515-519. PubMed ID: 33715009
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
